Clincosm LogoSign in Get a demo

Evaluation of Omeprazole Effect on Glaucoma

Sponsor
Shahid Beheshti University of Medical Sciences (Other)
Overall Status
Unknown status
CT.gov ID
NCT01000220
Collaborator
Ophthalmic Research Center (Other)
1
Location
2
Arms

Study Details

Study Description

Brief Summary

Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Evaluation of Omeprazole Effect on Glaucoma

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Omeprazole

Drug: Omeprazole
Placebo Comparator: placebo

Drug: Placebo

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • patients with glaucoma

    • 18 to 70 years

    • POAG patients, Pseudoexfoliation

    • no history of other systemic disease

    • no history of intraocular intervention

    • no history of H2 blocker or PPI consumption during the past month consuming 2 or less topical anti-glaucoma medication

    • no present immune deficiency

    • no addiction habit

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ophthalmic Research Center Tehran Iran, Islamic Republic of 166666

    Sponsors and Collaborators

    • Shahid Beheshti University of Medical Sciences
    • Ophthalmic Research Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01000220
    Other Study ID Numbers:
    • 8735
    First Posted:
    Oct 22, 2009
    Last Update Posted:
    May 4, 2010
    Last Verified:
    Oct 1, 2009
    Additional relevant MeSH terms:
    Glaucoma
    Omeprazole

    Study Results

    No Results Posted as of May 4, 2010